Drug intelligence / Profile preview

CartiPRO

Development stage: Unknown
Lead developer: Dalim Tissen
Modality: Recombinant Proteins and Enzymes
Administration: Intraarticular

Overview

CartiPRO is an intra-articular medical device developed by DALIM TISSEN Co., Ltd., composed of atelocollagen. Atelocollagen is a type of collagen treated to remove telopeptides, which significantly reduces its immunogenicity while maintaining its structural integrity. Injected directly into the knee joint, CartiPRO functions as a biological scaffold and lubricant intended to alleviate pain and support the repair of cartilage defects in patients suffering from knee osteoarthritis. It is designed to supplement the extracellular matrix of the joint, providing a microenvironment conducive to tissue stabilization and pain reduction. The product is typically administered in a series of injections to manage chronic joint symptoms.

Brand names: CartiPRO
Other names: atelocollagen injection

Beyond the preview

Go deeper on CartiPRO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CartiPRO.

Explore the full profile